Formerly Executive Director and Chief Research Executive of Johnson & Johnson (Aust), Dr Melrose lucidly explained the background to his technology some years ago: "It’s usual that antimicrobials are strong in safety, and weak in efficacy - or vice-versa.
"If it’s got enough grunt, it’s too toxic. If it’s safe enough, it hasn’t got enough grunt.
"We approached safety problem by making a polymer - it’s a very big molecule, like a string of sausages.
"And being big, it doesn’t easily go across membranes like skin or intestines.
"So it won’t go into the bloodstream like a normal drug will. Not getting to the bloodstream means it cannot manifest any toxicity.
"The other trump card is that our drug works differently from antibiotics.
So if the antibiotic does not go into the bloodstream, how are we expect to use it? In a tablet/pill format? But that gets administered through the intestines which Dr Melrose said it does go across easily. And it cannot be a topical application as he has covered that as well. Furthermore to the best of my knowledge, most antibiotics to be efficient are administered through the bloodstream. The only plausible route left is probably the aerosol route which if is correct would make administration of the antibiotics a breeze.
Perhaps if more disclosure is provided, I might be tempted to buy into this stock.
RCE Price at posting:
31.0¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)